Telo Genomics logo

TELO - Telo Genomics Share Price

C$0.52 0.0  4.0%

Last Trade - 5:30pm

Micro Cap
Market Cap £14.0m
Enterprise Value £13.6m
Revenue £n/a
Position in Universe 1473rd / 2679
Unlock TELO Revenue
Relative Strength (%)
1m -37.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -64.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 September 2020, TeloGenomics Corp revenues was not reported. Net loss decreased1% to C$137K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


TELO Revenue Unlock TELO Revenue

Net Income

TELO Net Income Unlock TELO Revenue

Normalised EPS

TELO Normalised EPS Unlock TELO Revenue

PE Ratio Range

TELO PE Ratio Range Unlock TELO Revenue

Dividend Yield Range

TELO Dividend Yield Range Unlock TELO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TELO EPS Forecasts Unlock TELO Revenue
Profile Summary

Telo Genomics Corp, formerly 3D Signatures Inc, is a Canada-based personalized medicine company with a software platform based on the three-dimensional (3D) analysis of telomere organization. Its TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and manage an individual’s disease based on their TeloViewTM score. Its software-based technology and prognostic methodology target various diseases that demonstrate genomic instability, including cancer and neurological disorders. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including TELO-HL, Telo-MM, Telo-PC, Telo-LC and Telo-AD. Its Telo-PC enables clinicians to identify patient stability during diagnosis, optimize treatment plans and manage to monitor with a non-invasive blood test. Its technology analyzes a specific part of an individual’s deoxyribonucleic acid to determine how a disease progress.

Last Annual June 30th, 2020
Last Interim September 30th, 2020
Incorporated May 25, 2011
Public Since February 15, 2012
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange TSX Venture Exchange
Shares in Issue 48,120,083
Free Float (0.0%)
Eligible for
TELO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TELO
Upcoming Events for TELO
Frequently Asked Questions for Telo Genomics
What is the Telo Genomics share price?

As of 5:30pm, shares in Telo Genomics are trading at C$0.52, giving the company a market capitalisation of £14.0m. This share price information is delayed by 15 minutes.

How has the Telo Genomics share price performed this year?

Shares in Telo Genomics are currently trading at C$0.52 and the price has moved by 0.144k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Telo Genomics price has moved by 0.118k% over the past year.

What are the analyst and broker recommendations for Telo Genomics?

There are no analysts currently covering Telo Genomics.

When will Telo Genomics next release its financial results?

Telo Genomics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Telo Genomics dividend yield?

Telo Genomics does not currently pay a dividend.

Does Telo Genomics pay a dividend?

Telo Genomics does not currently pay a dividend.

When does Telo Genomics next pay dividends?

Telo Genomics does not currently pay a dividend.

How do I buy Telo Genomics shares?

To buy shares in Telo Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Telo Genomics?

Shares in Telo Genomics are currently trading at C$0.52, giving the company a market capitalisation of £14.0m.

Where are Telo Genomics shares listed? Where are Telo Genomics shares listed?

Here are the trading details for Telo Genomics:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: TELO
What kind of share is Telo Genomics?

Based on an overall assessment of its quality, value and momentum, Telo Genomics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Telo Genomics share price forecast 2021?

We were not able to load any forecast data for Telo Genomics.

How can I tell whether the Telo Genomics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Telo Genomics. Over the past six months, the relative strength of its shares against the market has been 93.09%. At the current price of C$0.52, shares in Telo Genomics are trading at 65.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Telo Genomics PE Ratio?

We were not able to find PE ratio data for Telo Genomics.

Who are the key directors of Telo Genomics?

Telo Genomics's management team is headed by:

Sabine Mai - DRC
Hugh Rogers - IND
Ryan Cheung - CFO
Guido Baechler - CHM
Sherif Louis - PRE
John Meekison - IND
Who are the major shareholders of Telo Genomics?

Here are the top five shareholders of Telo Genomics based on the size of their shareholding:

Mai (Sabine) Individual Investor
Percentage owned: 5.84% (2.81m shares)
Palos Management Inc. Investment Advisor
Percentage owned: 5.71% (2.75m shares)
Palos WP Growth Fund Mutual Fund
Percentage owned: 5.71% (2.75m shares)
Rogers (Hugh A D) Individual Investor
Percentage owned: 1.64% (788k shares)
Cheung (Ryan E) Individual Investor
Percentage owned: 0.94% (450k shares)
Similar to TELO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.